CIK 0000748592 · Non-accelerated filer<br>Smaller reporting company
Ernexa Therapeutics Inc.
Sign in to watch- Ticker
- ERNA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 311103425
- Phone
- (617) 798-6700
- Business address
- 1035 CAMBRIDGE STREET, SUITE 18A, CAMBRIDGE, MA, 02141
- Former names
- Eterna Therapeutics Inc., Brooklyn ImmunoTherapeutics, Inc., NTN BUZZTIME INC, NTN COMMUNICATIONS INC
Securities
- ERNA Common Stock Nasdaq
- ERNAW Warrants Nasdaq
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 89 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-09-24 | Cherington Charles 10% owner | Sale · Warrants (right to buy) | −2,475,524 | 0 | ||
| 2024-09-24 | Cherington Charles 10% owner | Sale · Warrants (right to buy) | −3,125,976 | 0 | ||
| 2024-09-24 | Cherington Charles 10% owner | Purchase · 12.0% Senior Convertible Notes due September 24, 2025 | +0 | $1,368,626.00 | $0 | |
| 2024-09-23 | Cherington Charles 10% owner | Purchase · 6.0% Senior Convertible Promissory Notes due 2028 | +0 | |||
| 2024-09-23 | Cherington Charles 10% owner | Purchase · Warrants (right to buy) | +83,916 | 2,391,608 | ||
| 2024-09-23 | Cherington Charles 10% owner | Purchase · 6.0% Senior Convertible Promissory Notes due 2028 | +0 | |||
| 2024-09-23 | Cherington Charles 10% owner | Purchase · Warrants (right to buy) | +83,916 | 2,475,524 | ||
| 2024-06-21 | Gurrola Sandra M Sr. VP of Finance | Option exercise | +437 | 1,365 | ||
| 2024-06-21 | Gurrola Sandra M Sr. VP of Finance | Shares withheld for taxes | −180 | $1.94 | $349 | 1,185 |
| 2024-06-21 | Gurrola Sandra M Sr. VP of Finance | Option exercise · Restricted Stock Units | −437 | 437 | ||
| 2024-04-26 | Cicala Peter Director | Grant or award · Stock Option (Right to buy) | +88,946 | 88,946 | ||
| 2024-04-26 | Gurrola Sandra M Sr. VP of Finance | Grant or award · Stock Option (Right to buy) | +80,000 | 80,000 | ||
| 2024-04-26 | Bristol James Arthur Director | Grant or award · Stock Option (Right to buy) | +124,525 | 124,525 | ||
| 2024-01-01 | Luther Sanjeev President and CEO | Grant or award · Stock Option (right to buy) | +1,685,218 | 1,685,218 | ||
| 2024-01-01 | Clarke Dorothy J General Counsel | Grant or award · Stock Option (right to buy) | +168,521 | 168,521 | ||
| 2023-12-15 | Freebird Partners LP 10% owner | Purchase · Convertible Note Shares | +520,996 | $1.92 | $1000K | 783,233 |
| 2023-12-15 | Freebird Partners LP 10% owner | Purchase · Common Stock Purchase Warrant | +1,041,992 | 1,991,394 | ||
| 2023-12-14 | Cherington Charles 10% owner | Purchase · 12.0% Senior Convertible Notes | +0 | $3,000,000.00 | $0 | |
| 2023-12-14 | Cherington Charles 10% owner | Purchase · Warrants (right to buy) | +3,125,976 | $0.13 | $391K | 3,125,976 |
| 2023-12-14 | Cherington Charles 10% owner | Other disposition · Warrants (right to buy) | −2,307,692 | 0 |
Page 3 of 33 · 657 trades